Journals / Türk Nöroloji Dergisi / 2021 / Cilt: 27 - Sayı: 3

Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis?

Serum Endocan Düzeyleri Relapsing-Remitting Multipl Sklerozda Bir Vasküler Belirteç Olabilir mi?

Pages
257–262
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies including larger patient cohorts are needed to support our results.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Multiple sclerosis (MS) is a chronic degenerative and inflammatory disease leading to axonal damage and demyelination in the central nervous system.
📊
Key Findings & Data:Endothelial cell specific molecule-1 (ESM-1) (endocan) is expressed by endothelial cells under the control of cytokines, and increases in inflammatory processes involving the vascular endothelium.
💡
Conclusion & Impact:Further studies including larger patient cohorts are needed to support our results.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Multiple sclerosis (MS) is a chronic degenerative and inflammatory disease leading to axonal damage and demyelination in the central nervous system. Although the pathogenesis is still controversial, it is accepted that there is an immune-mediated inflammatory response. Endothelial cell specific molecule-1 (ESM-1) (endocan) is expressed by endothelial cells under the control of cytokines, and increases in inflammatory processes involving the vascular endothelium. In this study, we aimed to compare serum endocan levels along with other hematologic inflammatory markers [such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)] in patients with relapsing-remitting MS (RRMS) and healthy controls. We also aimed at investigating the role of vascular endothelial dysfunction in RRMS. Materials and Methods: We enrolled 64 patients with RRMS in the remission period, and 37 healthy controls in the study. We investigated hematologic parameters (ESR, CRP) and serum ESM-1 levels by enzyme-linked immunosorbent assay. Results were compared between two groups statistically. Results: The CRP and ESR had no significant difference between patients and controls (p=0.861 and p=0.76 respectively). Serum endocan levels of the patient group were significantly higher than the healthy controls (p=0.045). RRMS patients with or without treatment and comorbid diseases showed no significant difference in serum endocan levels (p=0.565 and p=0.169 respectively). The predictive value of endocan was 62.0%, cut-off value was 9124.7326 pg/l, sensitivity was 68.8%, and specificity was 54.1%. Conclusion: We demonstrated higher serum endocan levels in patients with RRMS in remission period, confirming the role of vascular inflammation. Further studies including larger patient cohorts are needed to support our results.

Özet

Amaç: Multipl skleroz (MS), santral sinir sisteminde demiyelinizasyon ve aksonal hasara yol açan kronik dejeneratif ve enflamatuvar bir hastalıktır. Patogenezi halen tartışmalı olsa da, altta yatan immün aracılıklı bir enflamatuvar yanıtın varlığı kabul edilmektedir. Endotelyal hücre spesifik molekül-1 (ESM-1) (endocan), endotel hücrelerinden sitokinlerin kontrolü altında salınan ve özellikle vasküler endoteli içeren enflamasyon esnasında salınımı artan bir moleküldür. Bu çalışmada serum endocan düzeyleri ve diğer hematolojik enflamasyon belirteçleri olan C-reaktif protein (CRP) ve eritrosit sedimentasyon hızı (ESR) seviyelerinin, relapsingremitting MS (RRMS) ve sağlıklı kontroller arasında kıyaslanarak, RRMS de vasküler endotelyal disfonksiyonun rolünün araştırılması amaçlanmıştır. Gereç ve Yöntem: Çalışmaya remisyon evresinde olan 64 RRMS hastası ve 37 sağlıklı kontrol dahil edildi. Hematolojik parametreler (ESR ve CRP) ve serum ESM-1 seviyeleri enzim-aracılıklı immünoabsorbsiyon yöntemi ile çalışıldı. Sonuçlar iki grup arasında istatistiksel olarak kıyaslandı. Bulgular: Hasta ve kontrol grupları arasında CRP ve ESR bakımından anlamlı bir fark bulunamadı (sırasıyla; p=0,861 ve p=0,76). Hasta grubunun serum endocan seviyeleri sağlıklı gruba oranla anlamlı düzeyde yükselmişti (p=0,045). Tedavi almakta olan ve almayan, ile komorbid hastalığı olan ve olmayan hasta grupları arasında serum endocan seviyeleri bakımından anlamlı farklılık bulunamadı (sırasıyla; p=0,565, p=0,169). Serum endocan seviyelerinin prediktif değeri %62,0 eşik değeri 9124,7326 pg/l, sensitivitesi %68,8 ve spesifitesi %54,1 olarak bulundu. Sonuç: Serum endocan seviyelerinin RRMS hastalarında remisyon evresinde yükselmesinin, RRMS’de vasküler enflamasyonun rolünü destekleyebileceğini düşünmekteyiz. Bu konuda daha geniş hasta sayıları ile yapılacak çalışmalara ihtiyaç bulunmaktadır.

🔖

Cite This Article

EMRE, U., ERDAL, Y., ATALAR, A. Ç., KÖSEOĞLU, M., YAVUZ, N., OĞUZ, O. (2022). Could Serum Endocan Be a Vascular Endothelial Marker in Relapsing-Remitting Multiple Sclerosis?. Türk Nöroloji Dergisi, Cilt: 27 - Sayı: 3, 257–262. https://ajindex.com/articles/636524

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Klotz L, Kuzmanov I, Hucke S, et al. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc Natl Acad Sci USA 2016;113:E6182-E6191
  2. Scheu S, Ali S, Mann-Nüttel R, et al. Interferon β-mediated protective functions of microglia in central nervous system autoimmunity. Int J Mol Sci 2019;20:E190
  3. Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Invest 2017;127:3577-3587
  4. Bendszus M, Storch-Hagenlocher B. Multiple Sclerosis and Other Demyelinating Diseases, Inflammatory Diseases of the Brain. Springer; 2013, pp. 3-18
  5. Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M. miR-326 and miR-26 a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing–remitting multiple sclerosis. Gene 2014;544:128-133
  6. Sánchez-López AL, Ortiz GG, Pacheco-Moises FP, et al. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis. Arch Med Res 2018;49:391-398
  7. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134:2755-2771
  8. Lemus HN, Warrington AE, Rodriguez M. Multiple Sclerosis: Mechanisms of Disease and Strategies for Myelin and Axonal Repair. Neurol Clin 2018;36:1-11
  9. Wang H, Wang K, Wang C, Zhong X, Qiu W, Hu X. Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis. Mult Scler 2013;19:926-931
  10. Minager A, Wenche JY, Jimenez JJ, Alexander JS. Multiple sclerosis as a vascular disease. Neurological Res 2006;28:230-235
  11. Jankowska-Lech I, Terelak-Borys B, Grabska-Liberek, I, et al. Endothelin-1 Plasma Levels in Multiple Sclerosis Patients: A Possible Factor of Vascular Dysregulation? Med Sci Monit 2015;21:1066-1071
  12. Spencer JI, Bell JS, DeLuca GC. Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier. J Neurol Neurosurg Psychiatry 2018;89:42-52
  13. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000;37:417-425
  14. Janke J, Engeli S, Gorzelniak K, et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 2006;38:28-33
  15. Wellner M, Herse F, Janke J, et al. Endothelial cell specificmo